Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 26740621
Coffey RT, et al. (2016) Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling. J Biol Chem 291, 5221-33 26740621
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  293T (epithelial), BaF3 ('B lymphocyte, precursor'), GP293 (fibroblast), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Cbz-B3A no change compared to control

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  293T (epithelial), BaF3 ('B lymphocyte, precursor'), GP293 (fibroblast), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Cbz-B3A no change compared to control
rapamycin decrease

S2481-p - mTOR (human)
Modsite: tVPEsIHsFIGDGLV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  293T (epithelial), BaF3 ('B lymphocyte, precursor'), GP293 (fibroblast), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Cbz-B3A no change compared to control

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  293T (epithelial), BaF3 ('B lymphocyte, precursor'), GP293 (fibroblast), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Cbz-B3A decrease 65?% inhibition
rapamycin decrease 100% inhibition